ALX Oncology shares rise 16.15% intraday after reporting phase 1b/2 trial data showing CD47 expression predicts drug activity in metastatic breast cancer and securing $150M in equity financing.
ByAinvest
Thursday, Feb 5, 2026 10:20 am ET1min read
ALXO--
ALX Oncology surged 16.15% intraday, driven by two key updates: 1) a $150 million financing round via 76.98 million shares and 18.57 million pre-funded warrants in February 2026 to strengthen capital, and 2) January 2026 clinical data showing CD47 expression predicts activity of evorpacept combined with ZIIHERA® in metastatic breast cancer. ALX Oncology is a clinical-stage immuno-oncology company focused on developing CD47 immune checkpoint inhibitors for cancer treatment.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet